IP6K2-IN-1 is a selective flavonoid-based IP6K2 inhibitor with an IC50 value of 0.55 μM. IP6K2-IN-1 shows higher inhibitory potency against IP6K2 than IP6K1 and IP6K3. IP6K2-IN-1 can be utilised as a hit compound for further structural modifications of IP6K2 inhibitors.

iNOs-IN-7 (example 4) is an inducible nitric oxide synthase (NOS) inhibitor. iNOs-IN-7 can be used for the study of inflammatory disease and pain.

Inolitazone hydrochloride hydrate (Efatutazone hydrochloride hydrate) is a novel PPARγ high-affinity agonist, with an EC50 value one-fiftieth that of Rosiglitazone, and shows no inhibitory effect on RIE cells that do not express PPARγ. Inolitazone hydrochloride hydrate can be used in the research of cancer.

Influenza virus-IN-10 is a dual-target antiviral agents for influenza that targets both PAC (KD = 8.9 μM) and NP (KD = 52.5 μM) simultaneously. Influenza virus-IN-10 exhibits an EC50 values of 1.64 μM) against influenza A virus (H1N1, A/WSN/33) and broad-spectrum activity against other influenza strains, including influenza B virus and multiple subtypes of influenza A.

Influenza A virus-IN-19 (Compound (S)-63) is an orally active, selective Influenza A virus inhibitor with an EC50 of 0.44 μM. Influenza A virus-IN-19 exhibits moderate binding affinity to Hemagglutinin, with a Kd of 5.66 μM. Influenza A virus-IN-19 inhibits trypsin-mediated cleavage of HA0, blocks the early viral entry process, and suppresses the replication of Influenza A virus. Influenza A virus-IN-19 improves the survival rate of mice in lethal influenza models. Influenza A virus-IN-19 can be used in studies related to Influenza A virus infection.

Influenza A virus-IN-17 (Compound 6a) is a potent influenza A inhibitor with EC90s of 3.5 μM and 2.6 μM for H3N2 and H1N1, respectively. Influenza A virus-IN-17 inhibits U2-PB2 chimeric mRNA (EC90 = 2.1 μM from cap snatching polymerase).

IND8 is a α7 nAChR activator and cognitive enhancer. IND8 mediates cognitive enhancement by activating α7 nAChR . IND8 improves spatial working memory, episodic short-term memory and spatial long-term memory in amnesic mice induced by Scopolamine. IND8 improves memory function in mice with delayed natural memory decline. IND8 can be used in research related to Alzheimer's disease.

INCB059872 TFA is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 TFA can be used for the research of myeloid leukemia.

iMQT_020 is a selective allosteric SLC1A5_var inhibitor. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. iMQT_020 reduces GSH levels and increases cellular ROS and mitochondrial ROS. iMQT_020 induces apoptosis and ferroptosis. iMQT_020 can epigenetically upregulate PD-L1 expression. iMQT_020 can be used for the study of pancreatic cancer, lung cancer, and colon cancer.

Immunosuppressant-2 (Example 21) is an orally active immunosuppressant. Immunosuppressant-2 significantly reduces the number of circulating lymphocytes. Immunosuppressant-2 can be used for research on various autoimmune diseases and organ transplant rejection.

Im-m7GDP is the cap reagent that can be used for nucleic acid synthesis.

Imidazole-4-pyruvic acid is derived from histidine catalyzed by histidine transaminase. Imidazole-4-pyruvic acid can be used as a precursor for selective His-labeling in E.coli overexpressed proteins.

IL-17-IN-7 (Compound 23) is a IL-17 inhibitor with a pIC50 of 7.1 against IL-17A.

IL-17-IN-6 is a IL-17 inhibitor with a pIC50 of 7.6 against human targets. IL-17-IN-6 binds to IL-17A and blocks downstream pro-inflammatory signaling pathways. IL-17-IN-6 inhibits the release of IL-6 from normal human skin fibroblasts stimulated by IL-17A and TNF. IL-17-IN-6 can be used for research on inflammatory and autoimmune diseases.

IL-17-IN-5 (Compound 3) is an IL-17 inhibitor with an IC50 of <0.1 μM. IL-17-IN-5 can be used in the research of inflammatory diseases.

IL-17-IN-4 (Compound 3) is an IL-17 inhibitor with an IC50 of less than 0.1 μM. IL-17-IN-4 can be used for the study of inflammatory diseases.

IKZF2-degrader 3 (compound 6) is a molecular glue IKZF2 degrader with a DC50 of 2.0 nM.

IKKε-IN-1 is a IKKε inhibitor. IKKε-IN-1 reduces cell viability, inhibits colony formation and cell migration. IKKε-IN-1 induces autophagy (Autophagy) in cancer cells. IKKε-IN-1 can be used in the research of cancers including colorectal cancer, hepatocellular carcinoma, bladder cancer, breast cancer, lung cancer, and cervical cancer.

IKKβ-IN-7 is an IKKβ inhibitor with an IC50 value of 9.44 μM. IKKβ-IN-7 induces DNA damage, S-phase cell cycle arrest, ROS accumulation, mitochondrial membrane potential loss, and apoptosis. IKKβ-IN-7 inhibits phosphorylation of p65 and IκBα, suppresses p65 nuclear translocation, and regulates NF-κB-controlled genes. IKKβ-IN-7 suppresses tumor growth in xenograft models and shows activity against colorectal cancer with low normal cell cytotoxicity. IKKβ-IN-7 can be used for the research of colorectal cancer.

IKKβ-IN-6 is an antitumor agent. IKKβ-IN-6 inhibits IKKβ (IC50: 18.24 μM), thereby suppressing the phosphorylation of p65 and IκBα, blocking the nuclear translocation of p65, and subsequently regulating genes controlled by NF-κB. IKKβ-IN-6 also targets topoisomerase I (Topo I), induces DNA damage, ROS accumulation, loss of mitochondrial membrane potential, and S-phase arrest. IKKβ-IN-6 is applicable to related research on colorectal cancer.

Ikarisoside B is a potent and selective Organic cation transporter 1 (OCT1) inhibitor with an IC50 of 11.18 μM. Ikarisoside B shows selectivity over OCT2 (IC50 = 56.54 μM). Ikarisoside B can be used for the research of metabolic disease.

IK-595 is a MEK1/MEK2 inhibitor with high affinity (7.39 nM).IK-595 blocks EGF-induced ERK1/2 phosphorylation in AsPC-1 cells with IC50 value of 0.1 nM. IK-595 has oral activity and blood-brain barrier penetration. IK-595 can be used for the research of Ras/MAPK pathway-altered cancers.

IHCH-3185 is an orally active class I HDAC inhibitor (HDAC1 IC50 =102.9 nM) and A2AR antagonist (A2AR Ki =7.6 nM). IHCH-3185 reverses immune gene silencing by inducing histone acetylation and blocks the adenosine signaling pathway to relieve T-cell suppression. IHCH-3185 exhibits antiproliferative activity, induces cell cycle arrest, and significantly improves the tumor microenvironment. IHCH-3185 reduces the proportion of regulatory T cells, increases the CD8+/Treg ratio, and upregulates the expression of key factors such as H2-K1, Cxcl9 and Cxcl10. IHCH-3185 shows significant antitumor potential in CT26 and MC38 mouse tumor models and is suitable for related cancer research.

IDO1-IN-32 (Compound 45) is a potent and orally effective IDO1 inhibitor with an IC50 of 10 pM. IDO1-IN-32 exhibits significant anti-proliferative activity against Hela cells. IDO1-IN-32 can significantly inhibit tumor growth in CT26 and LCC transplanted mouse models by activating anti-tumor immunity. IDO1-IN-32 can be used for research on colon cancer and breast cancer.

IDO1-IN-31 (Compound 17g) is an IDO1 agonist with an IC50 of 77 nM. IDO1-IN-31 can be used for the study of neurological diseases and cancers.

IDO1-IN-30 (Compound (R)-100) is a potent and highly selective IDO1 inhibitor. IDO1-IN-30 has an IC50 of 4.8 nM to IDO1 in SKOV3 cells. IDO1-IN-30 does not show significant cytotoxicity at 25 µM in HepG2 cells. IDO1-IN-30 can eliminate inhibition of CYP450 enzymes (such as 3A4, 2C9, 2D6). IDO1-IN-30 can be used for research on cancer and inflammatory conditions.

IDO1/TDO-IN-11 (Compound Y-13) is a dual IDO1 and TDO inhibitor, with an IC50 of 2.87 μM against hIDO1 and an IC50 of 0.08 μM against hTDO. IDO1/TDO-IN-11 inhibits NO production and ROS production. IDO1/TDO-IN-11 alleviates cellular neuroinflammatory damage and ameliorates Parkinson's disease. IDO1/TDO-IN-11 is applicable to research related to Parkinson's disease.

IDH1 ligand 1 (Compound 18) can serve as a negative control for the IDH1 target, with no detectable affinity for wild-type IDH1 and an IC50 >10,000 nM.

ICI-200880 is a potent, selective and reversible human neutrophil elastase (HNE) inhibitor. ICI-200880 is promising for research of inflammatory lung diseases related to neutrophil elastase, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).

ICI-170777 is an orally active cardiotonic agent. ICI-170777 enhances cardiac contractility and induces arteriovenous dilation in animal models of congestive heart failure. ICI-170777 can be used in research on cardiovascular and cerebrovascular diseases such as heart failure.